
![]() |
|||||||||||||
WJPR Citation Report
|
| All | Since 2021 | |
| Citation | 9186 | 4781 |
| h-index | 32 | 25 |
| i10-index | 256 | 108 |
A REVIEW ON ATYPICAL HEMOLYTIC UREMIC SYNDROME (aHUS)
*Dr. Subash Chandran M. P., Dr. Julia, Anju David Raj, Jeslin John, Pooja Sasi, Rizwana Muhammed
Abstract Atypical hemolytic uremic syndrome (aHUS) is a rare complementmediated kidney disease that primarily affects kidney function. aHUS is mostly related to gene mutations, coupled with a triggering event. The pathogenesis revolves around the inherited defects in complement genes and autoantibodies against complement regulatory proteins. The syndrome has a high mortality rate therefore has to be diagnosed early also to limit target organ damage. Diagnosis includes a complete blood count (CBC) test. It will measure the red blood cell and platelet count since its low counts can be a sign of aHUS. Treatment mainly involved plasma-based therapy prior to the availability of Eculizimab. Eculizumab has revolutionised the management of aHUS. Keywords: aHUS, complement regulatory proteins, Eculizumab, autoantibodies, CBC. [Full Text Article] [Download Certificate] |
